Mutation and Mutagenic Reasons Contributing to Parkinson's Disease Development

Arghadeep Sarkar[1], Ramesh Alluri[2], Gayathri Paturi[3], Lagde Nitin Balasaheb[4], Raja Shekar Perusomula[5]
[1,3,4]*Cognitive Science Research Initiative (CSRI) Lab, Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research (VIPER), Naraspur, 502313.*
[2] *Professor, Cognitive Science Research Initiative (CSRI) Lab, Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research (VIPER), Naraspur, 502313.*
[5]*Corresponding Author: Professor, Cognitive Science Research Initiative (CSRI) Lab, Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research (VIPER), Naraspur, 502313*
doi.org/10.64643/IJIRTV12I5-185703-459

***Abstract*—Parkinson's disease (PD) might be a energetic neurodegenerative clutter characterized by motor and non-motor side impacts that through and through debilitate the quality of life.is multifactorial, including both hereditary and natural variables. Later propels have uncovered an perplexing organize of transformations in a few qualities and the impact of natural mutagens that collectively contribute to dopaminergic neuron degeneration and degradationwithin the substantia nigra. This review investigates the mutational scene and mutagenic variables involved in PD, emphasizing atomic instruments, later discoveries, and their suggestions for future restorative techniques.**

***Index Terms*—Parkinson's disease; genetic mutations; SNCA; alpha-synuclein; transcriptional mutagenesis; 8-oxodG; oxidative stress.**

I. INTRODUCTION

PD influences over 10 million individuals around the world and remains a imposing challenge in neurology. The classical highlights of PD—resting tremor, bradykinesia, unbending nature, and postural instability—arise fundamentally from dopaminergic neuronal misfortune within the substantia nigra pars compacta. While maturing is the foremost conspicuous hazard calculate, a developing body of prove recommends that particular hereditary transformations and natural mutagens play basic parts in malady onset and movement (1). This review aims to dissect the genetic and environmental underpinnings of PD, drawing from recent high-impact research and review articles.While a multitude of reviews has elucidated the genetic and environmental factors and causes contributing to Parkinson's disease, the current review distinctly synthesizes the notion of transcriptional mutagenesis—specifically, the erroneous incorporation of nucleotides resulting from oxidative damage, such as 8-oxodG—as a mechanistic link between environmental mutagens and the accumulation of pathogenic proteins. By underscoring the synergistic outcomes of oxidative stress on the fidelity of DNA, the integrity of mitochondria, and the processes of protein clearance, this review presents a mutation-focused synthesis that integrates both sporadic and familial manifestations of PD within a unified biochemical paradigm.

II. GENETIC MUTATIONS CONTRIBUTING TO PARKINSON'S DISEASE

2.1 Novel Mechanistic Insight: Transcriptional Mutagenesis in SNCA

The SNCA quality encodes alpha-synuclein, a protein indispensably to synaptic vesicle direction. Point transformations (e.g., A53T, A30P, E46K) and quality increases lead to the amassing of misfolded alpha-synuclein and Lewy body arrangement (2). Studies have confirmed that these mutations are pathogenic, often leading to early-onset familial PD (3).

- Mutagenic Mechanism of SNCA via Transcriptional Mutagenesis

1. Oxidative DNA damage and 8-oxodG Arrangement:

• 8-oxo-7,8-dihydroguanine (8-oxodG) could be a predominant oxidative injury coming about from receptive oxygen species (ROS) connection with guanine bases in DNA.

• In PD, expanded oxidative push leads to the amassing of 8-oxodG in both atomic and mitochondrial DNA, especially inside dopaminergic neurons of the substantia nigra.(22)

2. Transcriptional Mutagenesis (TM) Prepare:

• Amid translation, RNA polymerase II may misread 8-oxodG as thymine, consolidating adenine rather than cytosine into the early mRNA.

• This misincorporation comes about in mutant mRNA transcripts without changing the basic DNA grouping.

• The mutant mRNAs are deciphered into abnormal α-synuclein proteins, which can have modified properties compared to the wild-type protein .

3. Results of Mutant α-Synuclein Proteins:

• Mutant α-synuclein variations, such as S42Y, display:

o Upgraded conglomeration affinity, driving to the arrangement of Lewy bodies.

o Expanded neurotoxicity, contributing to neuronal passing.

o Seeding capability, advancing conglomeration of wild-type α-synuclein.

4. Suggestions for Parkinson's disease Pathogenesis:

• TM-induced mutant α-synuclein proteins might play a critical part in both familial and intermittent shapes of PD.

• The amassing of these abnormal proteins can disturb cellular homeostasis, leading to neurodegeneration.

2.2 LRRK2 (Leucine-rich repeat kinase 2) LRRK2 mutations, particularly G2019S, are the most common genetic cause of late-onset familial

PD and are also form sporadic cases. LRRK2 modulates mitochondrial function and autophagy, and its pathogenic variants disrupt these processes, exacerbating neuronal vulnerability (4,5).

Mutagenic Mechanism of LRRK2 in Parkinson's Infection

1. *Hereditary Transformation and Pathogenic Variation*

• LRRK2 changes are the foremost common hereditary reason of late-onset familial PD and are too found in a few sporadic cases. (23,24)

• The foremost frequently recognized pathogenic transformation is G2019S, found within the kinase space, which increments LRRK2 kinase action unusually.

2. *Robotic Pathways of Mutagenicity*

a. Kinase Hyperactivation and Mitochondrial Stretch

• Transformed LRRK2 too much phosphorylates mitochondrial parting protein DLP1, advancing mitochondrial fracture, brokenness, and ROS era.

b. Impeded Antioxidant Defense by means of PRDX3

• LRRK2 interatomic with peroxiredoxin 3 (PRDX3), a key antioxidant in mitochondria.(23,24)

• The G2019S change hyperphosphorylates PRDX3, impeding its peroxidase action, in this way lifting oxidative push and ROS-induced harm.

c. Neuroinflammation and Astrocytic Brokenness

• Transformed LRRK2 contributes to glial actuation, expanding pro-inflammatory cytokines.

• In astrocytes, it disables lysosomal-autophagic pathways, compromising protein clearance.

d. Autophagy-Lysosomal Dysregulation

• LRRK2 transformations disturb autophagic flux and anticipate the clearance of harmed mitochondria (mitophagy).(23,24)

• This leads to the aggregation of broken organelles and cytotoxic protein totals in neurons and glia.

3. *Mutagenic Affect*

Whereas LRRK2 transformations are not classically "mutagenic" like TM in SNCA, they:

• By implication enhance mutagenesis and cell passing by expanding ROS, disabling mitochondrial DNA repair, and destabilizing redox adjust. (23,24)

2.3 PARK2 (Parkin) and PARK7 (DJ-1) Both PARK2 and PARK7 qualities are included in mitochondrial quality control and oxidative push reactions. Transformations in these qualities are related with autosomal latent adolescent parkinsonism. Parkin transformations result in disabled ubiquitin-proteasome work, whereas DJ-1 transformations ruin oxidative push detoxification (6,7).

Mutagenic Factor: Parkin (PARK2) in Parkinson's Disease

1. Genetic Background

The gene Parkin (PARK2) encodes a crucial E3 Ubiquitin ligase, which acts as an indispensable role in the Ubiquitination of impaired proteins and mitochondria, facilitating their subsequent degradation through the proteasomal and autophagy-lysosomal pathways. Genetic alterations in Parkin are implicated in autosomal recessive juvenile parkinsonism (AR-JP), recognized as one of the earliest-onset variants of Parkinson's Disease (PD).

2. Mutagenic Factors and Mechanism

a. Mitochondrial Dysfunction: ROS Production

Under normal physiological conditions, Parkin functions to remove damaged mitochondria through the process of mitophagy. However, genetic mutations disrupt this vital mechanism, resulting in the accumulation of dysfunctional mitochondria, which serve as a significant origin of reactive oxygen species (ROS).

b. ROS-Induced DNA Damage

Enhanced levels of ROS lead to the oxidation of various cellular constituents, encompassing DNA, proteins, and lipids. This oxidative stress culminates in the formation of DNA lesions, such as 8-oxodG, thereby heightening the probability of transcriptional inaccuracies and mutagenic events, particularly within post-mitotic neurons.

c. Inflammation and Neurotoxicity

A deficiency in Parkin augments the production of inflammatory cytokines, instigating neuroinflammation that may further exacerbate oxidative stress, induce DNA damage, and precipitate neuronal cell death.

d. Compromised Protein Clearance

Mutated forms of Parkin exhibit a loss of E3 ligase functionality, leading to an impaired ubiquitination process of misfolded or damaged proteins. The resultant accumulation of these proteins may function as pro-mutagenic agents, initiate cellular dysfunction and contribute to the degeneration of dopaminergic neurons.

2.4 PINK1 (PTEN-induced kinase 1) PINK1 changes compromise mitophagy by disabling the enlistment of Parkin to harmed mitochondria. This comes about within the amassing of broken mitochondria, a known trigger for neuronal passing in PD (8).

2.5 GBA (Glucocerebrosidase) Mutations Heterozygous transformations in GBA, with Gaucher's infection, increment the chance of creating PD. These changes impede lysosomal work and alpha-synuclein corruption, subsequently advancing neurodegeneration (9,10).

2.6 VPS35, CHCHD2, and Other Emerging GenesChanges in VPS35 (a retromer complex component) and CHCHD2 (connected to mitochondrial work) have been involved in familial PD. These qualities emphasize the significance of vesicular trafficking and mitochondrial elements in PD pathophysiology (11,12).

III. EPIGENETIC MODIFICATIONS AND SOMATIC MUTATIONS

Later considers have distinguished physical mosaicism and epigenetic modifications as extra layers of hereditary impact. DNA methylation changes in PD-related qualities and histone adjustments may worsen or relieve malady hazard (13).

3.1Transcriptional Mutagenesis as a Bridge Between Oxidative Stress and Alpha-Synuclein Aggregation

Recent investigations have elucidated transcriptional mutagenesis (TM) as a significant, albeit inadequately examined, factor contributing to the pathogenesis of Parkinson's disease (PD). In contrast to traditional DNA mutations that permanently modify the genetic code, TM arises from oxidative damage—mainly through the formation of 8-oxo-7,8-dihydroguanine (8-oxodG)—which induces RNA polymerase to misinterpret DNA during the transcriptional process without altering the DNA sequence itself. Within the dopaminergic neurons of the substantia nigra, heightened levels of reactive oxygen species (ROS) lead to extensive oxidative DNA damage, particularly at guanine-rich regions of the SNCA gene.During the process of TM, RNA polymerase II may erroneously perceive 8-oxodG as thymine, resulting in the joining of adenine in place of cytosine into the elongating RNA strand. This generates mutant mRNAs that encode aberrant α-synuclein proteins such as the S42Y variants which demonstrate increased aggregation propensity and

cytotoxicity. These modified proteins act as nucleation sites for the formation of Lewy bodies, even in the absence of mutations within the SNCA gene.This mechanism creates a nexus between genetic predispositions and environmental factors in the context of PD. Although SNCA mutations account for certain familial cases of PD, TM offers a viable explanation for α-synuclein-related pathologies observed in sporadic instances where no mutations at the DNA level are present. Furthermore, it emphasizes how oxidative stress—often triggered by environmental toxins—can mimic a "mutated protein environment" without resulting in permanent genetic modification.Consequently, transcriptional mutagenesis not only enhances our comprehension of α-synuclein-driven pathologies but also draws attention to the manner in which oxidative stress directly engenders functionally mutant proteins, signifying a convergence between inherited susceptibilities and environmental stimuli in the context of Parkinson's disease.

IV. ENVIRONMENTAL MUTAGENS AND PARKINSON'S DISEASE

4.1 Pesticides and Herbicides Pesticides like paraquat and rotenone has been unequivocally connected with expanded PD hazard. These chemicals initiate oxidative push and mitochondrial brokenness, mirroring PD-like pathology in creature models (14).
4.2 Heavy Metals Chronic exposure to heavy metals such as leadand manganese can damage dopaminergic neurons. Manganese, in particular, accumulates in the basal ganglia and causes motor symptoms similar to PD (15).
4.3 Solvents and Industrial Chemicals Trichloroethylene (TCE), a degreasing dissolvable, has been related with an expanded hazard of PD. TCE introduction influences mitochondrial work and may act synergistically with hereditary inclinations (16).
4.4 Air Pollution and NanoparticlesInward breath of fine particulate matter (PM2.5) and nanoparticles may contribute to neuroinflammation and oxidative stretch. Considers recommend a relationship between tall levels of discuss contamination and expanded PD rate (17).
4.5 Dietary Toxins and ContaminantsUtilization of nourishment sullied with neurotoxins like
BMAA (β-N-methylamino-L-alanine) has been connected to PD-like disorders in certain populaces, proposing a part for dietary mutagens (18).

V. GENE-ENVIRONMENT INTERACTIONS

PD pathogenesis isn't exclusively managed by qualities or environment, but regularly by their interaction. For occasion, people with diminished movement of detoxifying proteins (e.g., GSTs, CYP450s) due to hereditary polymorphisms may be more vulnerable to natural poisons (19).

VI. MOLECULAR PATHWAYS BRIDGING GENETIC AND ENVIRONMENTAL TRIGGERS

Both hereditary transformations and natural mutagens focalize on common pathogenic pathways:
oxidative push, mitochondrial brokenness, disabled autophagy, and alpha-synuclein conglomeration.
Understanding these pathways is significant for distinguishing helpful targets (20).

Table 1: Astrocytic Responses and Mechanism of Neurotoxicity induced by Parkinsonian Toxins

Toxin	Astrocyte Response	Mechanism
MPTP/MPP^+	Increased ROS production	Astrocytes metabolize MPTP to MPP^+, leading to oxidative stress and neuronal damage
Rotenone	Mitochondrial impairment	Disrupts mitochondrial complex I in astrocytes, causing energy deficits and ROS generation
Paraquat	Elevated oxidative stress	Induces ROS production in astrocytes, contributing to neuronal toxicity

VII. FUTURE DIRECTIONS AND THERAPEUTIC IMPLICATIONS

Rising methodologies such as quality treatment, CRISPR-based quality altering, and accuracy medication hold guarantee. In addition, distinguishing high-risk people through hereditary screening and moderating natural exposures may frame portion of a preventive methodology against PD (21). Astrocytes represent a crucial category of neural cell types that serve to safeguard neurons from deleterious stimuli associated with Parkinson's Disease (PD). Functioning optimally, astrocytes demonstrate their neuroprotective capabilities through the secretion of neurotrophic factors, the synthesis of antioxidants, the attenuation of proinflammatory cytokines, and the clearance of harmful aggregates, including α-synuclein and compromised mitochondria. (24) Nonetheless, astrocytic impairments, encompassing oxidative stress, inflammatory responses, autophagy deficiencies, and apoptotic processes, are frequently observed under pathological conditions linked to genetic mutations associated with PD, such as those affecting DJ-1, α-synuclein, LRRK2, PINK1, and parkin, as well as in experimental PD models utilizing neurotoxic agents, including paraquat, rotenone, MPTP/MPP+, and 6-OHDA. (24

Table 2: Astrocyte dysfunctions and mechanism by Parkinsonian genes

Gene	Astrocyte Dysfunction	Mechanism
SNCA (α-Synuclein)	Impaired α-synuclein clearance	Astrocytes internalize α-synuclein aggregates, leading to lysosomal overload and inflammation
PARK7 (DJ-1)	Reduced antioxidant capacity	Reduction of DJ-1 function increases ROS, leading to oxidative stress and mitochondrial dysfunction
PARK2 (Parkin)	Defective mitophagy	Impaired clearance of damaged mitochondria, resulting in increased oxidative stress
PINK1	Mitochondrial dysfunction	Disrupted mitochondrial quality control, leading to energy deficits and ROS accumulation
LRRK2	Altered autophagy and inflammation	Mutations affect lysosomal function and promote pro-inflammatory responses

Table 3: Major Genes Associated with Monogenic Parkinson's Disease

GeneName	PARKLocus	InheritancePattern	Approximate Prevalence(%)	ProteinFunction& Role in PD
GBA	PARK19	Autosomal Recessive(risk factor in heterozygous state)	2-31 (PD patients, variesbyethnicity)	Glucocerebrosidase; lysosomal enzyme involvedin lipidmetabolism; mutations lead to lysosomal dysfunction and alpha-synuclein accumulation.
PRKN	PARK2	Autosomal Recessive	Up to 77 (early-onset familial),10-20 (early-onset sporadic)	Parkin; E3 ubiquitin ligase engagedinprotein degradation and mitophagy.

Table 3: Major Genes Associated with Monogenic Parkinson's Disease				
GeneName	PARKLocus	InheritancePattern	Approximate Prevalence(%)	ProteinFunction& Role in PD
PINK1	PARK6	Autosomal Recessive	1-9 (early-onset, variesbyethnicity)	PTEN initiated putativekinase1; mitochondrial kinaseinvolvedin mitophagy.
DJ-1(*PARK7*)	PARK7	Autosomal Recessive	1-2(early-onset)	ProteindeglycaseDJ-1; protects against oxidative stress,involvedin mitochondrial homeostasis.
VPS35	PARK17	Autosomal Dominant	Rare	Vacuolar protein sorting 35; component of the retromer complex plays a role in intracellularprotein trafficking.

Table 4: Environmental Risk Factors Linked to Parkinson's Disease		
Environmental Factor	Level of Evidence	Potential Biological Mechanisms
Pesticides & Herbicides (e.g., paraquat, simazine, atrazine, lindane)	Strong	Mitochondrial dysfunction, oxidative stress, neuro-inflammation, α-synuclein aggregation
Heavy Metals (e.g., molybdenum, tungsten, cadmium)	Emerging	Oxidative stress, mitochondrial dysfunction, protein misfolding
AirPollution(Traffic-Related, PM2.5)	Moderate to Strong	Neuroinflammation,oxidative stress,translocationofparticles



Fig no.1: A summary of genetic and environmental elements that contribute to the progression of Parkinson's disease, including related signs and prevention methods. Genetic alterations like SNCA and LRRK2, alongside environmental influences like pesticides and disruptions to circadian rhythms, come together to provoke neurodegeneration.

VIII. CONCLUSION

The etiology of Parkinson's Disease (PD) is modulated by a confluence of genetic and environmental determinants. Genetic alterations in loci such as α-synuclein (SNCA), PTEN-induced putative kinase 1 (PINK1), parkin, DJ-1 (PARK7), and leucine rich repeat kinase 2 (LRRK2) are associated with hereditary manifestations of PD. Environmental agents, including heavy metals and neurotoxic substances, may also facilitate the onset of PD. A pivotal element in the pathophysiology of PD is the augmented production of reactive oxygen species (ROS), which possess the potential to inflict damage upon dopaminergic neurons. Astrocytes, which typically serve a protective function for neurons, can paradoxically contribute to the progression of PD when their normal functioning is disrupted.

Observations of mutations in α-SYN mRNA within PD specimens imply that transcriptional mutagenesis may be a contributing factor to the disease's manifestation.

Novelty: The study elucidates the role of 8-oxodG-mediated transcriptional mutagenesis in the generation of α-SYN mutants within the substantia nigra of individuals afflicted with PD. The identification of specific α-SYN TM variants, alongside their presence in Lewy bodies, enhances the comprehension of PD pathogenesis. The review accentuates the critical nature of astrocytic dysfunction in PD, particularly through the lens of endoplasmic reticulum stress and apoptotic pathways, which may serve as viable therapeutic targets.It is imperative to acknowledge that while the documents furnish significant insights, ongoing research remains essential to comprehensively elucidate and address the complexities of Parkinson's disease.

REFERENCES

[1] Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. *The Lancet*, 386(9996), 896–912.

[2] Polymeropoulos, M. H., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science*, 276(5321), 2045–2047.

[3] Chartier-Harlin, M. C., et al. (2004). Alpha-synuclein locus duplication causes Parkinson's disease. *The Lancet*, 364(9440), 1167–1169.

[4] Healy, D. G., et al. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *The Lancet Neurology*, 7(7), 583–590.

[5] Greggio, E., & Cookson, M. R. (2009). Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. *ASN Neuro*, 1(1).

[6] Kitada, T., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*, 392(6676), 605–608.

[7] Bonifati, V., et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science*, 299(5604), 256–259.

[8] Valente, E. M., et al. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science*, 304(5674), 1158–1160.

[9] Sidransky, E., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New England Journal of Medicine*, 361(17), 1651–1661.

[10] Mazzulli, J. R., et al. (2011). Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell*, 146(1), 37–52.

[11] Zimprich, A., et al. (2011). A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. *American Journal of Human Genetics*, 89(1), 168–175.

[12] Funayama, M., et al. (2015). CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. *The Lancet Neurology*, 14(3), 274–282.

[13] Masliah, E., et al. (2013). Epigenetic changes in Parkinson's disease. *Nature Reviews Neuroscience*, 14(11), 780–793.

[14] Tanner, C. M., et al. (2011). Rotenone, paraquat, and Parkinson's disease. *Environmental Health Perspectives*, 119(6), 866–872.

[15] Guilarte, T. R. (2010). Manganese and Parkinson's disease: a critical review and new findings. *Environmental Health Perspectives*, 118(8), 1071–1080.

[16] Gash, D. M., et al. (2008). Trichloroethylene: Parkinsonism and complex 1 mitochondrial

neurotoxicity. *Annals of Neurology*, 63(2), 184–192.

[17] Ritz, B., et al. (2016). Air pollution and Parkinson's disease: A systematic review and meta-analysis. *Environmental Research*, 147, 373–384.

[18] Cox, P. A., et al. (2016). Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. *Proceedings of the Royal Society B*, 283(1823), 20152397.

[19] Dick, F. D., et al. (2007). Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. *Occupational and Environmental Medicine*, 64(10), 666–672.

[20] Surmeier, D. J., et al. (2017). Selective neuronal vulnerability in Parkinson disease. *Nature Reviews Neuroscience*, 18(2), 101–113.

[21] Mullin, S., et al. (2020). Precision medicine in Parkinson's disease: emerging strategies and future directions. *Nature Reviews Neurology*, 16(7), 411–428.

[22] Sambuddha Basu, Goun Je, Yoon-Seong Kim Experimental & Molecular Medicine, 2015Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease

[23] DOI: 10.1038/emm.2015.54.

[24] Weng et al., 2018, The Sources of Reactive Oxygen Species and Its Possible Role in the Pathogenesis of Parkinson's Disease

[25] Kim et al., 2023, Role of Astrocytes in Parkinson's Disease Associated with Genetic Mutations and Neurotoxicants

[26] Basu et al., 2023https://doi.org/10.1007/s00401-023-02632-7